GI
CLBT icon

Gradient Investments’s Cellebrite CLBT Stock Holding History

Gradient Investments’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,400
Closed -$18.4K – 1848
2023
Q3 		$18.4K Buy
+2,400
New +$18K ﹤0.01% 690

Other funds holding CLBT

IIGPLP
IGP Investments (G.P.L.P.) Herzliya, Israel $6.25M AUM 18.64% 1-Year Est. Return
TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Gradient Investments's CLBT Position: Q4 2023 in Review

Gradient Investments sold out of Cellebrite (CLBT) in Q4 2023, closing a stake of 2,400 shares — an estimated $18.4K sold.

Gradient Investments first reported a position in CLBT in Q3 2023 and held it in 1 quarter. The position peaked at $18.4K in Q3 2023. 116 funds tracked by Wall St. Rank hold CLBT as of Q4 2023.

  • Gradient Investments reported no remaining Cellebrite position as of Q4 2023 after selling out during the quarter.
  • Gradient Investments sold 2,400 Cellebrite shares in Q4 2023, an estimated $18.4K.
  • Gradient Investments first reported a position in Cellebrite in Q3 2023 and held it in 1 quarter.
  • Gradient Investments's Cellebrite position peaked at $18.4K in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Cellebrite as of Q4 2023.

Based on Gradient Investments's 13F filing for Q4 2023, filed 18 Jan 2024.